Why there’s excitement and skepticism about new Alzheimer’s drug lecanemab – CBC
Full results of worldwide human trial involving 1,800 patients to be released Tuesday
Nov 26, 2022
Despite decades of research and billions of dollars, no treatment has ever definitively proven to slow the progression of Alzheimer’s disease.
Two pharmaceutical companies have developed a drug that they say does just that.
On Tuesday, the full results of a worldwide human trial of the drug, called lecanemab, will be released at an Alzheimer’s research conference in San Francisco.
The companies — Biogen of the U.S. and Eisai of Japan — have so far merely summarized the results of the human trial in a September news release. It said early-stage Alzheimer’s disease patients who received lecanemab over the study’s 18-month timeframe scored 27 per cent better on cognitive tests than those who’d received a placebo.
Read more: https://www.cbc.ca/news/health/alzheimers-disease-drug-lecanemab-human-trial-results-1.6664408
